CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted
Executive Summary
After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula
You may also be interested in...
Comparative Effectiveness Bill Calls For Private Group To Plan Research
While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings
Comparative Effectiveness Bill Calls For Private Group To Plan Research
While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings
CMS Open To ASPs For Radiopharmaceuticals; Congress Blocks Rate Cap
CMS is willing to consider switching Medicare Part B payment for radiopharmaceuticals to the average sales price formula, the agency says in proposed rules to update Medicare's hospital outpatient prospective payment system for 2009